Ciprofloxacin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ciprofloxacin: From Bacterial Infections to Diffuse Scleroderma
One-Sentence Summary
Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic used to treat a wide range of bacterial infections. The TxGNN model predicts it may be effective for Diffuse Scleroderma, with 0 clinical trials and 2 publications currently supporting this direction. The available evidence is exploratory and pilot-level, placing this prediction firmly at the research hypothesis stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Broad-spectrum bacterial infections (fluoroquinolone antibiotic class) |
| Predicted New Indication | Diffuse Scleroderma |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L4 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold (Research Question) |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Ciprofloxacin is not available in this Evidence Pack. Based on established pharmacological knowledge, Ciprofloxacin is a fluoroquinolone antibiotic that kills susceptible bacteria by inhibiting DNA gyrase (GyrA/GyrB) and topoisomerase IV (ParC/ParE), thereby blocking DNA replication and transcription. These targets are bacterial-specific, which ordinarily makes repurposing for immune-mediated or fibrotic diseases less intuitive.
The connection to diffuse scleroderma rests on a dual-mechanism hypothesis. First, ciprofloxacin has demonstrated antifibrotic properties beyond its antibacterial activity: in vitro studies have shown that it can suppress skin fibroblast proliferation and collagen synthesis. This is mechanistically relevant because scleroderma is pathologically characterized by abnormal dermal collagen deposition driven by activated fibroblasts. Second, patients with systemic sclerosis frequently develop small intestinal bacterial overgrowth (SIBO), and antibiotic treatment — including with ciprofloxacin — may relieve gastrointestinal symptoms such as malabsorption and chronic diarrhea.
Neither mechanism, however, directly targets the central pathological drivers of scleroderma such as TGF-β–mediated fibrosis or microvascular injury. The mechanistic link remains indirect, and the antifibrotic hypothesis has only been tested in a single small pilot trial. Further basic and translational research is needed before this prediction can be considered actionable.
Clinical Trial Evidence
Currently no related clinical trials are registered for Ciprofloxacin in Diffuse Scleroderma.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20507401 | 2010 | Pilot RCT | The Journal of Dermatology | Controlled, double-blind randomized pilot trial assessing whether oral ciprofloxacin reduces scleroderma severity; explored antifibrotic utility in skin based on fibroblast inhibition hypothesis |
| 7728404 | 1995 | Observational Study | British Journal of Rheumatology | Investigation of small bowel bacterial overgrowth (SIBO) in 24 systemic sclerosis patients with malabsorption; ciprofloxacin used as treatment for SIBO, addressing the gastrointestinal manifestation of the disease |
Singapore Market Information
Ciprofloxacin is currently not registered or marketed in Singapore. No HSA authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Note: Formal key warnings, contraindications, and drug interaction data are not available in this Evidence Pack. As a fluoroquinolone, Ciprofloxacin carries an FDA Black Box Warning for tendinitis, tendon rupture, peripheral neuropathy, and CNS effects — particularly relevant for patient selection in any future study design.
Conclusion and Next Steps
Decision: Hold (Research Question)
Rationale: Evidence supporting Ciprofloxacin for diffuse scleroderma is at the L4 (pilot/preclinical) stage, consisting of one small randomized pilot study and one observational study, with no registered clinical trials and no Singapore market authorization. The mechanistic link is biologically plausible but indirect, and insufficient to advance without additional basic and clinical validation.
To proceed, the following is needed:
- Full-text critical appraisal of PMID 20507401 (pilot RCT sample size, primary endpoints, and results)
- In vitro confirmation of ciprofloxacin's antifibrotic mechanism in scleroderma-relevant fibroblast models
- Retrieval of complete safety profile: TFDA/HSA package insert warnings, contraindications, and drug interaction data
- Detailed MOA data from DrugBank (DG002 remediation)
- Assessment of any potential drug-disease interaction risk (fluoroquinolone-associated peripheral neuropathy is an active safety concern; patients with scleroderma-related neuropathy should be carefully evaluated)
- If proceeding to a Phase 2 design, a biomarker-driven patient selection strategy (e.g., high SIBO burden vs. predominantly fibrotic phenotype) to clarify which patient subpopulation may benefit most
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.